Aurobindo Pharma’s arm inks agreement to acquire commercial operations in US

06 Sep 2018 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- Aurobindo Pharma USA Inc., has entered into an agreement to acquire commercial operations and three manufacturing facilities in USA from Sandoz Inc., USA, a Novartis Division.

The acquisition will provide a unique opportunity to acquire a premier US generics business with a sizable and broad portfolio across key therapeutic areas. The acquisition is expected to be completed during the calendar year 2019.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1180.25 13.20 (1.13%)
14-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1700.55
Dr. Reddys Lab 1186.45
Cipla 1434.60
Zydus Lifesciences 884.00
Lupin 2195.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×